ALNY vs MLYS · P/E 76, rev $1.29B vs $2.17B cap
Alnylam Pharmaceuticals Inc (ALNY) versus Mineralys Therapeutics, Inc. Common Stock (MLYS) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Mineralys Therapeutics, Inc. Common Stock (MLYS) is a biotechnology company listed on US.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
MLYS does not have a complete income-statement cache yet.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. MLYS currently screens at market cap $2.17B.
Not investment advice. Open the ALNY and MLYS stock pages for the full models.
Not investment advice.